Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study

PURPOSE: Proteasome inhibitors are effective in Waldenström's macroglobulinemia (WM) but require parenteral administration and are associated with polyneuropathy. We investigated efficacy and toxicity of the less neurotoxic oral proteasome inhibitor ixazomib combined with rituximab, in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Kersten, Marie José, Amaador, Karima, Minnema, Monique C., Vos, Josephine M. I., Nasserinejad, Kazem, Kap, Marcel, Kastritis, Efstathios, Gavriatopoulou, Maria, Kraan, Willem, Chamuleau, Martine E. D., Deeren, Dries, Tick, Lidwine W., Doorduijn, Jeanette K., Offner, Fritz, Böhmer, Lara H., Liu, Roberto D., Pals, Steven T., Dimopoulos, Meletios A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683241/
https://www.ncbi.nlm.nih.gov/pubmed/34388022
http://dx.doi.org/10.1200/JCO.21.00105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683241/
https://www.ncbi.nlm.nih.gov/pubmed/34388022
http://dx.doi.org/10.1200/JCO.21.00105

Ejemplares similares